# Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19.

> **NCT04912011** · PHASE4 · UNKNOWN · sponsor: **Pomeranian Medical University Szczecin** · enrollment: 50 (estimated)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** Canrenoate Potassium
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT04912011
- **Lead sponsor:** Pomeranian Medical University Szczecin
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2021-08-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2021-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04912011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04912011, "Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19.". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT04912011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*